BrainsWay Ltd. (NASDAQ:BWAY) Sees Significant Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 80,200 shares, an increase of 27.3% from the January 31st total of 63,000 shares. Based on an average daily volume of 67,400 shares, the days-to-cover ratio is presently 1.2 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of BrainsWay in a report on Monday, December 23rd.

Institutional Investors Weigh In On BrainsWay

Several large investors have recently added to or reduced their stakes in BWAY. Lazard Asset Management LLC purchased a new position in BrainsWay during the 4th quarter worth $44,000. JPMorgan Chase & Co. grew its position in shares of BrainsWay by 316.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after buying an additional 11,221 shares in the last quarter. Sei Investments Co. purchased a new position in shares of BrainsWay during the fourth quarter valued at $149,000. Cubist Systematic Strategies LLC raised its holdings in shares of BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after acquiring an additional 2,446 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after acquiring an additional 2,144 shares in the last quarter. 30.11% of the stock is owned by hedge funds and other institutional investors.

BrainsWay Stock Down 1.5 %

BrainsWay stock traded down $0.15 during midday trading on Thursday, reaching $9.55. 12,862 shares of the stock traded hands, compared to its average volume of 68,736. BrainsWay has a 12 month low of $4.61 and a 12 month high of $11.79. The stock’s fifty day moving average is $10.21 and its 200-day moving average is $9.53. The stock has a market cap of $179.80 million, a P/E ratio of 95.51 and a beta of 1.29.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.